机构：[1]Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, 38 Xueyuan Road, Haidian District, Beijing 100191, China ; Department of Preventive Medicine, College of Medicine, Shihezi University, Shihezi 832002, China.[2]Department of Physiology, Capital Medical University, Beijing 100069, China.[3]Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, 38 Xueyuan Road, Haidian District, Beijing 100191, China ; Department of Statistics, Graduate School of Arts and Sciences, Columbia University, New York, NY 10027, USA.[4]Department of Orthopedics, Tianjin Fifth Central Hospital, Tianjin 300450, China.[5]Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, 38 Xueyuan Road, Haidian District, Beijing 100191, China ; Shantou-Oxford Clinical Research Unit, Shantou University Medical College, Shantou 515041, China.[6]Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, 38 Xueyuan Road, Haidian District, Beijing 100191, China.[7]Department of Endocrinology and Metabolism, People's Hospital, Peking University, Beijing 100044, China.
To evaluate the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on weight reduction in patients with Type 2 diabetes mellitus (Type 2 DM), a network meta-analysis was conducted. MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov were searched from 1950 to October 2013. Randomized controlled trials (RCTs) involving GLP-1 RAs were included if they provided information on body weight. A total of 51 RCTs were included and 17521 participants were enrolled. The mean duration of 51 RCTs was 31 weeks. Exenatide 10 μg twice daily (EX10BID) reduced weight compared with exenatide 5 μg twice daily (EX5BID), liraglutide 0.6 mg once daily (LIR0.6QD), liraglutide-1.2 mg once daily (LIR1.2QD), and placebo treatment, with mean differences of -1.07 kg (95% CI: -2.41, -0.02), -2.38 kg (95% CI: -3.71, -1.06), -1.62 kg (95% CI: -2.79, -0.43), and -1.92 kg (95% CI: -2.61, -1.24), respectively. Reductions of weight treated with liraglutide-1.8 mg once daily (LIR1.8QD) reach statistical significance (-1.43 kg (95% CI: -2.73, -0.15)) versus LIR1.2QD and (-0.98 kg (95% CI: -1.94, -0.02)) versus placebo. Network meta-analysis found that EX10BID, LIR1.8QD, and EX2QW obtained a higher proportion of patients with weight loss than other traditional hypoglycemic agents. Our results suggest GLP-1 RAs are promising candidates for weight control in comparison with traditional hypoglycemic drugs, and EX10BID, LIR1.8QD, and EX2QW rank the top three drugs.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2014]版：
大类|3 区医学
小类|4 区内分泌学与代谢4 区医学：研究与实验
最新[2023]版：
大类|3 区医学
小类|3 区内分泌学与代谢3 区医学：研究与实验
JCR分区：
出版当年[2013]版：
Q4ENDOCRINOLOGY & METABOLISMQ4MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版：
Q2ENDOCRINOLOGY & METABOLISMQ2MEDICINE, RESEARCH & EXPERIMENTAL
第一作者机构：[1]Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, 38 Xueyuan Road, Haidian District, Beijing 100191, China ; Department of Preventive Medicine, College of Medicine, Shihezi University, Shihezi 832002, China.
推荐引用方式(GB/T 7714)：
Sun Feng,Chai Sanbao,Li Lishi,et al.Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.[J].Journal of diabetes research.2015,2015:157201.doi:10.1155/2015/157201.
APA：
Sun Feng,Chai Sanbao,Li Lishi,Yu Kai,Yang Zhirong...&Zhan Siyan.(2015).Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis..Journal of diabetes research,2015,
MLA：
Sun Feng,et al."Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.".Journal of diabetes research 2015.(2015):157201
